US pharmaceutical firm Moderna says it will try to expand the use of its COVID-19 vaccine to people aged 12 and older, as it has confirmed the shot is safe and effective for adolescents.
Moderna announced the results of its clinical study on about 3,700 adolescents aged 12 to 17 on Tuesday.
The US Food and Drug Administration authorized the emergency use of the vaccine for people aged 18 and older in December.
In the study, a vaccine efficacy rate of 93 percent was observed more than 14 days after the first dose. Moderna says that, following the second dose, no cases of COVID-19 were observed after 14 days.
It says no significant safety concerns have been identified so far. That is reportedly consistent with a study, which involved people aged 18 and older. The company says it will continue monitoring the participants of the study.
Moderna says it "will submit these results to the US FDA and regulators globally in early June and request authorization" to expand the use of the vaccine to adolescents aged 12 to 17.
A vaccine developed by the US firm Pfizer and its German partner BioNTech has already been approved by the United States for people aged 12 and older.